Science that is transforming lives and enabling the future

Magnetic Bead Removal Using Microcarrier and Cell Separation System

All Posts

Magnetic Bead Removal Using Microcarrier and Cell Separation System

Inconsistent results and deviation are major issues in cell therapy manufacturing, primarily resulting from historically manual methods, scarcity of proprietary tools, and lack of operator training. With this difficult process also comes another hurdle–time. Providing a safe vein-to-vein transmission is critical when a patient is waiting (in many cases) for lifesaving therapy. How can we bridge the gap between speed, quality, safety, and consistency?


Magnetic beads have been the benchmark for cell and gene therapy (CGT), and the FDA holds strict requirements for their removal in CGT processing. Current methods require expensive, complex equipment, costly infrastructure, and highly skilled personnel. Despite specialized training, a single individual still needs to operate the process impeccably each time and avoid risking contamination.


blog-inline-12693-600x630Through the Magnetic Bead Removal Using Microcarrier and Cell Separation Study, Entegris’ microcarrier and cell separation system was incorporated into an optimized bioreactor subculturing process to maximize viable cell recovery and obtain a high split ratio between bioreactors during scale-up. At the end of each bioreactor run, a small volume of culture was taken as a representative sample of the entire culture. This sample was processed using the conventional tube method and the yield obtained was considered 100% cell recovery.


With customized chamber and mesh sizes (10 - 200 µm), the microcarrier and cell separation system can be used for a wide array of applications such as retaining aggregate cells or microcarrier beads, cell washing, and harvest, all while achieving the same or better performance as alternative separation methods.


Our closed microcarrier and cell separation system provides scalability, compatibility with a wide array of microcarriers, and can reduce deviations . Entegris is the only manufacturer of small bags specifically built for cells. By partnering with us, you’ll be able to increase yield, reduce deviations, and avoid the risk of residual beads in your final product.


To learn more read our application note


Related Posts

Reducing our Environmental Impact: How We’re Making Biopharma Manufacturing More Sustainable

Biopharma manufacturing is an essential part of the healthcare industry, producing lifesaving treatments for patients around the world. Traditional manufacturing methods can have a significant environmental impact driven by stainless steel equipment requiring extensive cleaning and sterilization processes that consume substantial amounts of water and energy in addition to cleaning agents.

Achieving the Third Dimension Through Molecular Modeling

For decades, the semiconductor device manufacturing mantra was “How do we make them smaller, cheaper, and faster?” The pursuit of Moore’s Law – the doubling of transistors on a chip every two years – was achieved through planar scaling. But that approach could only go on for so long. The mantra now is “How do we improve power, performance, area, and cost (PPAC)?” At the 14 nm node, it was clear that the best way to push the limits of semiconductor device PPAC was to take it into the third dimension.

Entegris and Agilitech: Transforming Single-Use Technologies

Entegris is delighted to announce our collaboration with Agilitech, a pioneering partner to the biotech industry. Agilitech provides highly flexible, scalable, and future-proof single-use technologies for every step of the bioprocess. These include chromatography systems, mixers, and custom-tailored bioprocess controllers that scale from the laboratory to commercial production environments. This makes them a natural fit for the unique needs of life sciences customers.